



Glucagon-like-Peptide-1 (GLP-1) clinico-genomic dataset for drug discovery and development

Helix, a leader in population genomics running the largest precision clinical network, is offering end-to-end genomics solutions that leverage our growing GLP-1 linked clinico-genomic database of recontactable individuals into actionable insights for diabetes and obesity research.



Comprehensive Whole Exome Sequencing Platform

The first and only FDA de novo class II authorized exome platform (Exome+®) optimized to be the most comprehensive and technically sensitive WES offering available.



Differentiated Clinical Data

De-identified, OMOP-standardized EHR integrations, including full clinical data & lab results, within US network. Ongoing data refreshes enable continued following of patient journey beyond initial encounter.

Proprietary Clinico-Genomic Database & Support



Exome+® sequencing data linked with rich longitudinal clinical data from a network of US health systems



Multi-site network protocol aggregating databases for a range of therapeutic areas



Geographically and demographically diverse population consented for Life Sciences re-contact



World class analytical capabilities and a dedicated in-house Research Services team

The power of Exome+® to drive drug discovery and preclinical research



Target Identification and Validation



New Biomarker Discovery




Understanding Disease Mechanism

Research-ready linked cohort for GLP-1 related conditions


Leveraging our geographically extensive network of health system partners across the US, Helix has built a rapidly growing clinico-genomic cohort of over 5,000 GLP-1 agonist treated patients

Therapeutic agents assessed (short and long acting):
 Exenatide, Liraglutide, Lixisenatide, Albiglutide, Dulaglutide, Semaglutide, Beinsaglutide, Tirzepatide


GLP-1 Cohort: Diabetes vs. Non



% of patients with X number of measurements



% Total Cohort vs. BMI Reading



Type 2 Diabetes:
 Identify and analyze *GLP1R* variants associated with Type 2 diabetes



GLP-1 custom cohort:
 Created based upon a range of inclusion criteria



Obesity:
 Analyze the emerging impact of GLP-1 agonists in obesity



Pharmacogenomics of GLP-1 agonist response:
 2023 study by Dawed, et al. demonstrates the robust utility of genomic data to analyze variants related to therapeutic response.

- 1 Built a clinical cohort of T2D patients treated with GLP-1 receptor agonists
- 2 Conducted GWAS analysis which provided novel insights on GLP-1 signaling and individuals with specific variants benefitting from earlier treatment with GLP-1 receptor agonists

Helix's cohort of >5,000 linked clinico-genomic records of GLP-1 agonist treated patients enable Life Sciences to expand similar studies and drive drug development with:



Research ready datasets:
 Easy to access and ready to drive impact for your needs



Custom delivered insights:
 Flexible solution enabling you to work with us on quick analysis or end-to-end research projects for T2D, Obesity and more.

